Navigation Links
Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs
Date:8/31/2009

TUSTIN, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical director of Massachusetts General Hospital (MGH) Cancer Center, chief of hematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished 25-year career at the National Cancer Institute (NCI), including serving as scientific director and director of the Division of Cancer Treatment. He has received numerous honors and awards, including the U.S. Public Health Service's Distinguished Service Award for his leadership in the development and approval of paclitaxel (Taxol(R)), a mainstay of current cancer therapy.

Dr. Chabner joins a group of advisors that have been assisting Peregrine in planning for the next stage of clinical trials for its bavituximab and Cotara(R) cancer programs. Bavituximab is currently being evaluated in three Phase II clinical trials in patients with advanced breast and lung cancer. Encouraging preliminary data from ongoing bavituximab clinical trials was presented at the 2009 Annual Meeting of the American Society of Clinical Oncology.

"Bavituximab's novel mechanism that enables the patient's immune system to attack tumors more effectively combined with its natural synergy with chemotherapy make it an intriguing and promising new approach to treating solid tumors," said Dr. Chabner. "The early clinical data on bavituximab is encouraging and I look forward to assisting Peregrine as they advance the bavituximab cancer program into late
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
3. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
4. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
5. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
6. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
7. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
10. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
11. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Continuing its commitment to finding a cure ... community, SmartPractice® donated $25,000 to HonorHealth Breast ... Vice President of Human Resources Meg Mosher and SmartScrubs ... to Paulla Miller, Sherry Gage, Dr. Linda Greer and ... on April 30. The center is located at 19646 ...
(Date:5/27/2015)... Allred Dental located in San Marcos, CA ... need extensive dental treatment - understand the oral issues they ... their problems. , Dr. Jeff Allred calls it “Dental Case ... assessment of the patient’s oral health and problems together with ... oral health problems. , “The dental case planning process starts ...
(Date:5/27/2015)... 27, 2015 Black Book Rankings, ... surveys in the multiple services and software industries, ... the highest ranked Electronic Health and Medical Record ... special research focus on implemented EHR users, Black ... vendors with the highest scores in client experience ...
(Date:5/27/2015)... The MedSpa at Hendrick is excited ... treatments in Abilene, Texas: Xeomin®, Belotero Balance® and Radiesse®. ... glabellar lines, better known as the lines between the ... to treat smoker’s lines around the mouth and marionette ... improves the appearance of smile lines or lines around ...
(Date:5/27/2015)... Coco Libre announced today that artists and audiences at ... Coconut Water to quench their thirst during the festival May ... artist greenrooms, corporate skyboxes and concessions areas at the venue. ... festival shuttle buses. , “We’re excited to have Coco ... of Strategic Partnerships for Latitude 38 Entertainment, producer of the ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... , TACOMA, Wash., July 10 Bridge of Life - ... bringing life-saving dialysis to developing countries, announced the grand opening ... the Philippines. Located in San Carlos, the new dialysis ... 250,000 residents in the surrounding communities who previously had no ...
... , WASHINGTON, July 10 The Council for American ... geneticist Dr. Francis Collins to head the National Institutes ... http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ) , , ... and a true pioneer in medical innovation," said Council ...
... Fitness Management Group, Inc. (the "Company"), parent company of ... Company has filed a voluntary petition under Chapter 11 ... for the Western District of North Carolina (the "Bankruptcy ... Capital LLC, a Nevada Limited Liability Company (the "Acquirer" ...
... , WASHINGTON, July 10 Americans United for Life (AUL) ... has been called to testify at the confirmation hearings for ... , AUL President Charmaine Yoest said "We are honored ... about the nomination of Judge Sotomayor to the highest court ...
... July 10 Physicians for Human Rights ... wake of a major New York Times story ... three federal investigations into alleged war crimes in Afghanistan in 2002. ... to investigate why the Bush Administration impeded an FBI criminal probe ...
... 10 The supervisory board of Celesio AG has ... in pharmaceutical wholesaler Panpharma. This step into one of ... part of Celesio,s growth strategy. Celesio doesn,t plan to ... Celesio spent about two years thoroughly analysing the Brazilian ...
Cached Medicine News:Health News:U.S. Non-Profit Announces Opening of Life-Saving Dialysis Facility in Philippines 2Health News:U.S. Non-Profit Announces Opening of Life-Saving Dialysis Facility in Philippines 3Health News:Council for American Medical Innovation Applauds Appointment of Geneticist Francis Collins to Head National Institutes of Health 2Health News:Fitness Management Group, Inc. Approves Sale of the Company 2Health News:Americans United for Life President to Testify at Sotomayor Senate Judiciary Hearing 2Health News:New Evidence that Bush Administration Impeded 3 Investigations into Alleged Massacre of Up to 2,000 Prisoners in Afghanistan 2Health News:New Evidence that Bush Administration Impeded 3 Investigations into Alleged Massacre of Up to 2,000 Prisoners in Afghanistan 3Health News:New Evidence that Bush Administration Impeded 3 Investigations into Alleged Massacre of Up to 2,000 Prisoners in Afghanistan 4Health News:Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma 2
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "2015 Strategies in ...  report to their offering.       ... report contains 500 pages, 120 tables, and ... potential market entrants identify and evaluate business ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: Type ... 2023 Summary Type 1 diabetes (T1D) is an ... islet, which means that the body can no longer produce ... evolving continuously, as at present, no other treatment can be ... A variety of insulin analogs with different times of action ...
(Date:5/27/2015)... May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering. ... issues pertaining to the US NAT laboratory ... demographic, social and technological trends with significant ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4United States Nucleic Acid Testing Market Strategies 2015-2020 2
... NARBERTH, Pa., May 22, 2012  Millennium Surgical Corp. / ... to assist nurses and scrub techs who perform ... The resource center provides detailed pictures and ... to protect and sterilize surgical instruments, rigid endoscopes, ...
... May 22, 2012  Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics today reported ... rats and dogs for its lead proprietary anorexigenic ... anorexigenic peptide selectively targeting the amylin receptor, is ...
Cached Medicine Technology:Millennium Surgical Corp. Develops Online Sterilization Resource Center 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 3Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 4Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 5
Straight shafts and serrated handle with polished finish. Teeth: Fine 1 x 2 teeth. Most popular size or model....
Straight shafts with delicate 0.7 mm, 1 x 2 teeth. Serrated handle with polished finish....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
Medicine Products: